Medicilon assists Insilico Medicine in obtaining approval for MAT2A inhibitor in both China and the United States
Recently, ISM3412, a class 1 new drug developed by InSilico Medicine Cayman TopCo (Insilico Medicine), received implied approval for clinical trials in China. The indication is for advanced/metastatic solid tumors. ISM3412 is a highly selective oral MAT2A inhibitor discovered with the assistance of artificial intelligence. It received FDA approval in April 2024 to conduct clinical trials in the United States for the treatment of MTAP- deficient cancers. As a strategic partner of Insilico Medicine, Medicilon provided preclinical research services for ISM3412, including pharmacokinetics and safety evaluation tests . This support laid a solid foundation for the rapid approval of the drug. "Synthetic Lethality" New Target MAT2A ISM3412 is expected to become "Best-in-Class" ISM3412 is a structurally novel and highly selective MAT2A inhibitor, designed with the assistance of Insilico Medicine's generative chemistry engine, Chemistry42, using ...